Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3493)
All Articles published online
|
Sep 28, 2009 (publication date) through Apr 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liang J, Deng X, Lin ZX, Zhao LC, Zhang XL. Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis. World J Gastroenterol 2009; 15(36): 4529-4537 [PMID: 19777611 DOI: 10.3748/wjg.15.4529] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i36/4529.htm |
| Number | Citing Articles |
| 1 |
Carlos Pérez-Monter, Aldo Torre-Delgadillo. Astrocyte - Physiology and Pathology. 2018; doi: 10.5772/intechopen.72506
|
| 2 |
P. D. J. Dunne, J. A. Fallowfield. Editorial: getting bullish about portal hypertension—chronic treatment with oral taurine?. Alimentary Pharmacology & Therapeutics 2018; 47(4): 533 doi: 10.1111/apt.14444
|
| 3 |
Harikumar Nair, Annalisa Berzigotti, Jaime Bosch. Emerging therapies for portal hypertension in cirrhosis. Expert Opinion on Emerging Drugs 2016; 21(2): 167 doi: 10.1080/14728214.2016.1184647
|
| 4 |
Xing-Qiu Liang, Jian Liang, Xiao-Fang Zhao, Xin-Yuan Wang, Xin Deng. Integrated network analysis of transcriptomic and protein-protein interaction data in taurine-treated hepatic stellate cells. World Journal of Gastroenterology 2019; 25(9): 1067-1079 doi: 10.3748/wjg.v25.i9.1067
|
| 5 |
Eric Felli, Yelidousi Nulan, Sonia Selicean, Cong Wang, Jordi Gracia-Sancho, Jaume Bosch. Emerging Therapeutic Targets for Portal Hypertension. Current Hepatology Reports 2023; 22(1): 51 doi: 10.1007/s11901-023-00598-4
|
| 6 |
Qinglu Xu, Tianzhu Luan, Songbin Fu, Jian Yang, Chao Jiang, Fangfang Xia. Effects of Pitavastatin on the Expression of VCAM‐1 and its Target Gene miR‐126 in Cultured Human Umbilical Vein Endothelial Cells. Cardiovascular Therapeutics 2014; 32(5): 193 doi: 10.1111/1755-5922.12081
|
| 7 |
R. Schwarzer, D. Kivaranovic, M. Mandorfer, R. Paternostro, D. Wolrab, B. Heinisch, T. Reiberger, M. Ferlitsch, C. Gerner, M. Trauner, M. Peck‐Radosavljevic, A. Ferlitsch. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Alimentary Pharmacology & Therapeutics 2018; 47(1): 86 doi: 10.1111/apt.14377
|
| 8 |
Susana G. Rodrigues, Yuly P. Mendoza, Jaime Bosch. Investigational drugs in early clinical development for portal hypertension. Expert Opinion on Investigational Drugs 2022; 31(8): 825 doi: 10.1080/13543784.2022.2095259
|
| 9 |
Gangadhar Surabhi, Shubhajit Dhara, Anusree Maneesh, Kajal Chakraborty, Lokanatha Valluru, Sambasiva Reddy Chenchula. Polygalacto-fucopyranose from marine alga as a prospective antihypertensive lead. International Journal of Biological Macromolecules 2021; 183: 589 doi: 10.1016/j.ijbiomac.2021.04.140
|
| 10 |
Jordi Gracia-Sancho, Giusi Marrone, Anabel Fernández-Iglesias. Hepatic microcirculation and mechanisms of portal hypertension. Nature Reviews Gastroenterology & Hepatology 2019; 16(4): 221 doi: 10.1038/s41575-018-0097-3
|
| 11 |
Ji-Yao Sheng, Zi-Fan Meng, Qiao Li, Yong-Sheng Yang. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension. Hepatobiliary & Pancreatic Diseases International 2024; 23(1): 4 doi: 10.1016/j.hbpd.2023.08.003
|
| 12 |
Hongyue Ma, Jiejun Jiang, Junfeng Zhang, Jing Zhou, Anwei Ding, Gaohong Lv, Huiqin Xu, Fenqiang You, Zhen Zhan, Jinao Duan. Protective effect of taurine on cardiotoxicity of the bufadienolides derived from toad (Bufo bufo gargarizansCanto) venom in guinea-pigsin vivoandin vitro. Toxicology Mechanisms and Methods 2012; 22(1): 1 doi: 10.3109/15376516.2011.583295
|
| 13 |
Marina Vilaseca, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Jordi Gracia-Sancho. Advances in therapeutic options for portal hypertension. Therapeutic Advances in Gastroenterology 2018; 11: 175628481881129 doi: 10.1177/1756284818811294
|
| 14 |
Natural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver Fibrosis. Cells 2019; 8(11): 1356 doi: 10.3390/cells8111356
|
| 15 |
Can-Jie Guo, Qin Pan, Hua Xiong, Yu-Qi Qiao, Zhao-Lian Bian, Wei Zhong, Li Sheng, Hai Li, Lei Shen, Jing Hua, Xiong Ma, Jing-Yuan Fang. Dynamic expression of miR‐126∗ and its effects on proliferation and contraction of hepatic stellate cells. FEBS Letters 2013; 587(23): 3792 doi: 10.1016/j.febslet.2013.09.047
|
| 16 |
Johannes Wiegand, Florian van Bömmel, Andrés Duarte-Rojo, José Altamirano, Juan G. Abraldes, Augusto Villanueva, Thomas Berg. Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. Journal of Hepatology 2016; 64(6): 1428 doi: 10.1016/j.jhep.2016.02.020
|
| 17 |
Can-Jie Guo, Qin Pan, Hua Xiong, Yu-Qi Qiao, Zhao-Lian Bian, Wei Zhong, Li Sheng, Hai Li, Lei Shen, Jing Hua, Xiong Ma. Therapeutic Potential of MicroRNA: A New Target to Treat Intrahepatic Portal Hypertension?. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/797898
|
| 18 |
Philipp Schwabl, Wim Laleman. Novel treatment options for portal hypertension. Gastroenterology Report 2017; 5(2): 90 doi: 10.1093/gastro/gox011
|
| 19 |
Asbjørn Gildberg, Jan Arne Arnesen, Bjørn-Steinar Sæther, Jaran Rauø, Even Stenberg. Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (Pandalus borealis) and identification of two novel inhibitory tri-peptides. Process Biochemistry 2011; 46(11): 2205 doi: 10.1016/j.procbio.2011.08.003
|
| 20 |
Tomoko Tadokoro, Asahiro Morishita, Tsutomu Masaki. Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA. International Journal of Molecular Sciences 2021; 22(15): 8139 doi: 10.3390/ijms22158139
|